How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets

Journal of Medicinal Chemistry

Volumn 59, Issue 6, 2016, Pages 2312-2327

  Doak, Bradley C ^a   Zheng, Jie ^a   Dobritzsch, Doreen ^a   Kihlberg, Jan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOUNDS ACCORDING TO CHEMICAL STRUCTURE; DRUG; LIGAND; MACROCYCLIC COMPOUND; NONMACROCYCLE; UNCLASSIFIED DRUG; DRUG RECEPTOR; PROTEIN BINDING;

BINDING AFFINITY; BINDING SITE; DRUG BINDING; DRUG CONFORMATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; MOLECULAR INTERACTION; PRACTICE GUIDELINE; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; CHEMICAL DATABASE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; METABOLISM;

ANIMALS; DATABASES, CHEMICAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LIGANDS; MOLECULAR CONFORMATION; PROTEIN BINDING; RECEPTORS, DRUG;

EID: 84962163302     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01286     Document Type: Review

References (59)

1. Rask-Andersen, M.; Almen, M. S.; Schioth, H. B. Trends in the exploitation of novel drug targets Nat. Rev. Drug Discovery 2011, 10, 579-590 10.1038/nrd3478
2. Bunnage, M. E. Getting pharmaceutical R&D back on target Nat. Chem. Biol. 2011, 7, 335-339 10.1038/nchembio.581
3. Kinch, M. S.; Hoyer, D.; Patridge, E.; Plummer, M. Target selection for FDA-approved medicines Drug Discovery Today 2015, 20, 784-789 10.1016/j.drudis.2014.11.001
4. Scannell, J. W.; Blanckley, A.; Boldon, H.; Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discovery 2012, 11, 191-200 10.1038/nrd3681
5. Hay, M.; Thomas, D. W.; Craighead, J. L.; Economides, C.; Rosenthal, J. Clinical development success rates for investigational drugs Nat. Biotechnol. 2014, 32, 40-51 10.1038/nbt.2786
6. Cook, D.; Brown, D.; Alexander, R.; March, R.; Morgan, P.; Satterthwaite, G.; Pangalos, M. N. Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework Nat. Rev. Drug Discovery 2014, 13, 419-431 10.1038/nrd4309
7. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome Nature 2004, 431, 931-945 10.1038/nature03001
8. Kim, M. S.; Pinto, S. M.; Getnet, D.; Nirujogi, R. S.; Manda, S. S.; Chaerkady, R.; Madugundu, A. K.; Kelkar, D. S.; Isserlin, R.; Jain, S.; Thomas, J. K.; Muthusamy, B.; Leal-Rojas, P.; Kumar, P.; Sahasrabuddhe, N. A.; Balakrishnan, L.; Advani, J.; George, B.; Renuse, S.; Selvan, L. D.; Patil, A. H.; Nanjappa, V.; Radhakrishnan, A.; Prasad, S.; Subbannayya, T.; Raju, R.; Kumar, M.; Sreenivasamurthy, S. K.; Marimuthu, A.; Sathe, G. J.; Chavan, S.; Datta, K. K.; Subbannayya, Y.; Sahu, A.; Yelamanchi, S. D.; Jayaram, S.; Rajagopalan, P.; Sharma, J.; Murthy, K. R.; Syed, N.; Goel, R.; Khan, A. A.; Ahmad, S.; Dey, G.; Mudgal, K.; Chatterjee, A.; Huang, T. C.; Zhong, J.; Wu, X.; Shaw, P. G.; Freed, D.; Zahari, M. S.; Mukherjee, K. K.; Shankar, S.; Mahadevan, A.; Lam, H.; Mitchell, C. J.; Shankar, S. K.; Satishchandra, P.; Schroeder, J. T.; Sirdeshmukh, R.; Maitra, A.; Leach, S. D.; Drake, C. G.; Halushka, M. K.; Prasad, T. S.; Hruban, R. H.; Kerr, C. L.; Bader, G. D.; Iacobuzio-Donahue, C. A.; Gowda, H.; Pandey, A. A draft map of the human proteome Nature 2014, 509, 575-581 10.1038/nature13302
9. Wilhelm, M.; Schlegl, J.; Hahne, H.; Moghaddas Gholami, A.; Lieberenz, M.; Savitski, M. M.; Ziegler, E.; Butzmann, L.; Gessulat, S.; Marx, H.; Mathieson, T.; Lemeer, S.; Schnatbaum, K.; Reimer, U.; Wenschuh, H.; Mollenhauer, M.; Slotta-Huspenina, J.; Boese, J. H.; Bantscheff, M.; Gerstmair, A.; Faerber, F.; Kuster, B. Mass-spectrometry-based draft of the human proteome Nature 2014, 509, 582-587 10.1038/nature13319
10. Rask-Andersen, M.; Masuram, S.; Schioth, H. B. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication Annu. Rev. Pharmacol. Toxicol. 2014, 54, 9-26 10.1146/annurev-pharmtox-011613-135943
11. Hopkins, A. L.; Groom, C. R. The druggable genome Nat. Rev. Drug Discovery 2002, 1, 727-730 10.1038/nrd892
12. Venkatesan, K.; Rual, J. F.; Vazquez, A.; Stelzl, U.; Lemmens, I.; Hirozane-Kishikawa, T.; Hao, T.; Zenkner, M.; Xin, X.; Goh, K. I.; Yildirim, M. A.; Simonis, N.; Heinzmann, K.; Gebreab, F.; Sahalie, J. M.; Cevik, S.; Simon, C.; de Smet, A. S.; Dann, E.; Smolyar, A.; Vinayagam, A.; Yu, H.; Szeto, D.; Borick, H.; Dricot, A.; Klitgord, N.; Murray, R. R.; Lin, C.; Lalowski, M.; Timm, J.; Rau, K.; Boone, C.; Braun, P.; Cusick, M. E.; Roth, F. P.; Hill, D. E.; Tavernier, J.; Wanker, E. E.; Barabasi, A. L.; Vidal, M. An empirical framework for binary interactome mapping Nat. Methods 2009, 6, 83-90 10.1038/nmeth.1280
13. Zhang, Q. C.; Petrey, D.; Deng, L.; Qiang, L.; Shi, Y.; Thu, C. A.; Bisikirska, B.; Lefebvre, C.; Accili, D.; Hunter, T.; Maniatis, T.; Califano, A.; Honig, B. Structure-based prediction of protein-protein interactions on a genome-wide scale Nature 2012, 490, 556-560 10.1038/nature11503
14. Arkin, M. R.; Tang, Y.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality Chem. Biol. 2014, 21, 1102-1114 10.1016/j.chembiol.2014.09.001
15. Surade, S.; Blundell, T. L. Structural biology and drug discovery of difficult targets: the limits of ligandability Chem. Biol. 2012, 19, 42-50 10.1016/j.chembiol.2011.12.013
16. Seco, J.; Luque, F. J.; Barril, X. Binding site detection and druggability index from first principles J. Med. Chem. 2009, 52, 2363-2371 10.1021/jm801385d
17. Krasowski, A.; Muthas, D.; Sarkar, A.; Schmitt, S.; Brenk, R. DrugPred: A structure-based approach to predict protein druggability developed using an extensive nonredundant data set J. Chem. Inf. Model. 2011, 51, 2829-2842 10.1021/ci200266d
18. Perola, E.; Herman, L.; Weiss, J. Development of a rule-based method for the assessment of protein druggability J. Chem. Inf. Model. 2012, 52, 1027-1038 10.1021/ci200613b
19. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48, 2518-2525 10.1021/jm049131r
20. Terrett, N. Drugs in middle space MedChemComm 2013, 4, 474-475 10.1039/c2md90062a
21. Doak, B. C.; Over, B.; Giordanetto, F.; Kihlberg, J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates Chem. Biol. 2014, 21, 1115-1142 10.1016/j.chembiol.2014.08.013
22. Abad-Zapatero, C. A sorcerer's apprentice and the rule of five: from rule-of-thumb to commandment and beyond Drug Discovery Today 2007, 12, 995-997 10.1016/j.drudis.2007.10.022
23. Zhang, M.-Q.; Wilkinson, B. Drug discovery beyond the rule-of-five' Curr. Opin. Biotechnol. 2007, 18, 478-488 10.1016/j.copbio.2007.10.005
24. Walters, W. P. Going further than Lipinski's rule in drug design Expert Opin. Drug Discovery 2012, 7, 99-107 10.1517/17460441.2012.648612
25. Villar, E. A.; Beglov, D.; Chennamadhavuni, S.; Porco, J. A., Jr; Kozakov, D.; Vajda, S.; Whitty, A. How proteins bind macrocycles Nat. Chem. Biol. 2014, 10, 723-731 10.1038/nchembio.1584
26. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery-an underexploited structural class Nat. Rev. Drug Discovery 2008, 7, 608-624 10.1038/nrd2590
27. Giordanetto, F.; Kihlberg, J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 2014, 57, 278-295 10.1021/jm400887j
28. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: A large-scale bioactivity database for drug discovery Nucleic Acids Res. 2012, 40, D1100-1107 10.1093/nar/gkr777
29. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26 10.1016/S0169-409X(00)00129-0
30. Bickerton, G. R.; Paolini, G. V.; Besnard, J.; Muresan, S.; Hopkins, A. L. Quantifying the chemical beauty of drugs Nat. Chem. 2012, 4, 90-98 10.1038/nchem.1243
31. Vieth, M.; Sutherland, J. J. Dependence of molecular properties on proteomic family for marketed oral drugs J. Med. Chem. 2006, 49, 3451-3453 10.1021/jm0603825
32. Morphy, R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds J. Med. Chem. 2006, 49, 2969-2978 10.1021/jm0512185
33. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39 10.1038/nrc2559
34. Nero, T. L.; Morton, C. J.; Holien, J. K.; Wielens, J.; Parker, M. W. Oncogenic protein interfaces: small molecules, big challenges Nat. Rev. Cancer 2014, 14, 248-262 10.1038/nrc3690
35. Wirth, M.; Volkamer, A.; Zoete, V.; Rippmann, F.; Michielin, O.; Rarey, M.; Sauer, W. H. Protein pocket and ligand shape comparison and its application in virtual screening J. Comput.-Aided Mol. Des. 2013, 27, 511-524 10.1007/s10822-013-9659-1
36. Volkamer, A.; Kuhn, D.; Grombacher, T.; Rippmann, F.; Rarey, M. Combining global and local measures for structure-based druggability predictions J. Chem. Inf. Model. 2012, 52, 360-372 10.1021/ci200454v
37. Huang, B. MetaPocket: A meta approach to improve protein ligand binding site prediction OMICS 2009, 13, 325-330 10.1089/omi.2009.0045
38. Ruddigkeit, L.; van Deursen, R.; Blum, L. C.; Reymond, J. L. Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17 J. Chem. Inf. Model. 2012, 52, 2864-2875 10.1021/ci300415d
39. Luo, J.; Guo, Y.; Zhong, Y.; Ma, D.; Li, W.; Li, M. A functional feature analysis on diverse protein-protein interactions: Application for the prediction of binding affinity J. Comput.-Aided Mol. Des. 2014, 28, 619-629 10.1007/s10822-014-9746-y
40. Clackson, T.; Wells, J. A. A hot spot of binding energy in a hormone-receptor interface Science 1995, 267, 383-386 10.1126/science.7529940
41. Bogan, A. A.; Thorn, K. S. Anatomy of hot spots in protein interfaces J. Mol. Biol. 1998, 280, 1-9 10.1006/jmbi.1998.1843
42. Schmidtke, P.; Barril, X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites J. Med. Chem. 2010, 53, 5858-5867 10.1021/jm100574m
43. Rosenquist, A.; Samuelsson, B.; Johansson, P. O.; Cummings, M. D.; Lenz, O.; Raboisson, P.; Simmen, K.; Vendeville, S.; de Kock, H.; Nilsson, M.; Horvath, A.; Kalmeijer, R.; de la Rosa, G.; Beumont-Mauviel, M. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor J. Med. Chem. 2014, 57, 1673-1693 10.1021/jm401507s
44. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discovery 2006, 5, 993-996 10.1038/nrd2199
45. Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121 10.1038/nrd4163
46. Kenny, P. W.; Leitao, A.; Montanari, C. A. Ligand efficiency metrics considered harmful J. Comput.-Aided Mol. Des. 2014, 28, 699-710 10.1007/s10822-014-9757-8
47. Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D. Ligand binding efficiency: trends, physical basis, and implications J. Med. Chem. 2008, 51, 2432-2438 10.1021/jm701255b
48. Mallinson, J.; Collins, I. Macrocycles in new drug discovery Future Med. Chem. 2012, 4, 1409-1438 10.4155/fmc.12.93
49. Chen, I. J.; Foloppe, N. Tackling the conformational sampling of larger flexible compounds and macrocycles in pharmacology and drug discovery Bioorg. Med. Chem. 2013, 21, 7898-7920 10.1016/j.bmc.2013.10.003
50. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623 10.1021/jm020017n
51. Varma, M. V.; Obach, R. S.; Rotter, C.; Miller, H. R.; Chang, G.; Steyn, S. J.; El-Kattan, A.; Troutman, M. D. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination J. Med. Chem. 2010, 53, 1098-1108 10.1021/jm901371v
52. He, M. W.; Lee, P. S.; Sweeney, Z. K. Promiscuity and the conformational rearrangement of drug-like molecules: insight from the Protein Data Bank ChemMedChem 2015, 10, 238-244 10.1002/cmdc.201402389
53. Haupt, V. J.; Daminelli, S.; Schroeder, M. Drug promiscuity in PDB: protein binding site similarity is key PLoS One 2013, 8, e65894 10.1371/journal.pone.0065894
54. DeLorbe, J. E.; Clements, J. H.; Whiddon, B. B.; Martin, S. F. Thermodynamic and structural effects of macrocyclic constraints in protein-ligand interactions ACS Med. Chem. Lett. 2010, 1, 448-452 10.1021/ml100142y
55. Watts, K. S.; Dalal, P.; Tebben, A. J.; Cheney, D. L.; Shelley, J. C. Macrocycle conformational sampling with MacroModel J. Chem. Inf. Model. 2014, 54, 2680-2696 10.1021/ci5001696
56. Sondergaard, C. R.; Garrett, A. E.; Carstensen, T.; Pollastri, G.; Nielsen, J. E. Structural artifacts in protein-ligand X-ray structures: implications for the development of docking scoring functions J. Med. Chem. 2009, 52, 5673-5684 10.1021/jm8016464
57. Liebeschuetz, J.; Hennemann, J.; Olsson, T.; Groom, C. R. The good, the bad and the twisted: A survey of ligand geometry in protein crystal structures J. Comput.-Aided Mol. Des. 2012, 26, 169-183 10.1007/s10822-011-9538-6
58. Baker, M. Fragment-based lead discovery grows up Nat. Rev. Drug Discovery 2013, 12, 5-7 10.1038/nrd3926
59. Marsault, E.; Peterson, M. L. Macrocycles are great cycles: Applications, opportunities, and challenges of synthetic macrocycles in drug discovery J. Med. Chem. 2011, 54, 1961-2004 10.1021/jm1012374